PXAs are semi-benign brain tumors that share molecular and morphological commonalities with traditional LEATs, such as CD34 immunoreactivity in 73% of cases of PXAs (Thom et al., 2012) and BRAFV600E mutation in 50–75% of analyzed PXAs (Schindler et al., 2011). Here, CD34 is linked to brain neoplasm.